ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Sertaç Çiçek
Ufuk Demirkiliç
Harun Tatar
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Çiçek, S.
Right arrow Articles by Tatar, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Çiçek, S.
Right arrow Articles by Tatar, H.

Ann Thorac Surg 1996;61:1372-1376
© 1996 The Society of Thoracic Surgeons


Original Articles: Cardiovascular

Postoperative Aprotinin: Effect on Blood Loss and Transfusion Requirements in Cardiac Operations

Sertaç Çiçek, MD, Ufuk Demirkiliç, MD, Erkan Kuralay, MD, Ertugrul Özal, MD, Harun Tatar, MD

Department of Cardiovascular Surgery, GATA Gülhane School of Medicine, Ankara, Turkey

Accepted for publication January 10, 1996.

Background. Aprotinin has been used increasingly to reduce postoperative blood loss in open heart operations. Although it was reported as safe in earlier studies, the overall safety of prophylactic use has been questioned recently. Because of the potential for complications and the high cost, it will be reasonable to use aprotinin more selectively in the postoperative period.

Methods. We prospectively studied the effect of postoperative low-dose aprotinin (2 million kallikrein inactivator units [280 mg]) on blood loss and transfusion requirements in patients undergoing cardiopulmonary bypass. Seventy-five patients were randomly assigned to three groups: prophylactic high-dose aprotinin (group 1), postoperative aprotinin (group 2), or a nonmedicated control group (group 3).

Results. The three groups were comparable in all demographic and operative variables. Postoperative chest tube drainage was significantly decreased in both aprotinin groups compared with that in the control group (295 mL in group 1 and 325 mL in group 2 versus 411 mL in group 3; p< 0.05). No significant difference was seen between the two aprotinin groups. The use of homologous blood products was significantly less in group 1 and group 2 than in group 3 (1.15 ± 1.13 U and 1.35 ± 1.30 U versus 2.55 ± 1.09 U; p < 0.05).

Conclusions. Our results suggest that postoperative aprotinin reduces blood loss and transfusion requirements comparably with prophylactic high-dose aprotinin. Thus, one can restrict its use to patients with excessive postoperative bleeding.




This article has been cited by other articles:


Home page
CirculationHome page
J. R. Brown, N. J.O. Birkmeyer, and G. T. O'Connor
Meta-Analysis Comparing the Effectiveness and Adverse Outcomes of Antifibrinolytic Agents in Cardiac Surgery
Circulation, June 5, 2007; 115(22): 2801 - 2813.
[Abstract] [Full Text] [PDF]


Home page
Clin TrialsHome page
D. Fergusson, K. C. Glass, B. Hutton, and S. Shapiro
Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding?
Clinical Trials, June 1, 2005; 2(3): 218 - 232.
[Abstract] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
J. M. Alvarez, L. R. Jackson, C. Chatwin, and J. J. Smolich
Low-dose postoperative aprotinin reduces mediastinal drainage and blood product use in patients undergoing primary coronary artery bypass grafting who are taking aspirin: A prospective, randomized, double-blind, placebo-controlled trial
J. Thorac. Cardiovasc. Surg., September 1, 2001; 122(3): 457 - 463.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
M. J. Ray, M. M. Hales, L. Brown, M. F. O'Brien, and E. G. Stafford
Postoperatively administered aprotinin or epsilon aminocaproic acid after cardiopulmonary bypass has limited benefit
Ann. Thorac. Surg., August 1, 2001; 72(2): 521 - 526.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
F. Forestier, S. Belisle, D. Robitaille, R. Martineau, L. P. Perrault, and J.-F. Hardy
Low-dose aprotinin is ineffective to treat excessive bleeding after cardiopulmonary bypass
Ann. Thorac. Surg., February 1, 2000; 69(2): 452 - 456.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1996 by The Society of Thoracic Surgeons.